2021
Functional connectivity of the default mode, dorsal attention and fronto-parietal executive control networks in glial tumor patients
Tordjman M, Madelin G, Gupta P, Cordova C, Kurz S, Orringer D, Golfinos J, Kondziolka D, Ge Y, Wang R, Lazar M, Jain R. Functional connectivity of the default mode, dorsal attention and fronto-parietal executive control networks in glial tumor patients. Journal Of Neuro-Oncology 2021, 152: 347-355. PMID: 33528739, PMCID: PMC8204932, DOI: 10.1007/s11060-021-03706-w.Peer-Reviewed Original ResearchConceptsSeed-based connectivity analysisFronto-parietal networkDefault mode networkHigh-grade gliomasFunctional connectivityFronto-parietal executive control networkGlioma patientsIncreased connectivityFunctional magnetic resonance imagingCorpus callosumDisruption of functional connectivityExecutive control networkPosterior cingulate gyrusPosterior corpus callosumMagnetic resonance imagingResults35 patientsDMN connectivityFrontal cortexMode networkCingulate gyrusDorsal attentionGlial tumorsTumor patientsDecreased connectivityIDH1-R132H
2020
Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.
Arrillaga-Romany I, Kurz S, Tarapore R, Sumrall A, Butowski N, Harrison R, De Groot J, Chi A, Shonka N, Umemura Y, Odia Y, Mehta M, Nghiemphu P, Cloughesy T, Lu G, Oster W, Allen J, Batchelor T, Lassman A, Wen P. Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma. Journal Of Clinical Oncology 2020, 38: 3615-3615. DOI: 10.1200/jco.2020.38.15_suppl.3615.Peer-Reviewed Original ResearchH3 K27M-mutant diffuse midline gliomaBlinded independent central reviewPhase II clinical trialDiffuse midline gliomaII clinical trialsMidline gliomaTreatment discontinuation due to toxicityClinical trialsDiffuse midline glioma patientsDiscontinued due to toxicityH3 K27M-mutant gliomasNon-contrast-enhancing regionsGlioma patientsObjective response rateDuration of responseDopamine receptor expressionIndependent central reviewContrast-enhancing lesionsH3 K27MFirst-in-classT1 post-contrastAnti-cancer small moleculesStable diseaseData cutoffPrior radiationClinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma.
Kawakibi A, Tarapore R, Gardner S, Kurz S, Wen P, Arrillaga-Romany I, Batchelor T, Butowski N, Sumrall A, Shonka N, Harrison R, De Groot J, Mehta M, Odia Y, Hall M, Cloughesy T, Ellingson B, Umemura Y, Allen J, Koschmann C. Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma. Journal Of Clinical Oncology 2020, 38: 3617-3617. DOI: 10.1200/jco.2020.38.15_suppl.3617.Peer-Reviewed Original ResearchH3 K27M-mutant gliomasNon-recurrent patientsGlioma patientsRecurrent patientsClinical efficacyTreatment discontinuation due to toxicityDiscontinued due to toxicityMedian duration of responseH3 K27M-mutantDose-limiting toxicityDuration of responseDiffuse midline gliomaExpression of DRD2Wild-type gliomasAntitumor responseMedian followMidline gliomaPrimary tumorRecurrent diseaseDRD2 expressionMedian durationDRD2 antagonistsMedian ageTumor DNAMedian time
2019
HOUT-29. THE INFLUENCE OF PSYCHIATRIC ILLNESS ON OUTCOME AND CANCER CARE RECEIVED IN PATIENTS WITH GLIOMAS
Patel P, Li T, Chou J, Patel A, Crispino S, Utate M, Kurz S. HOUT-29. THE INFLUENCE OF PSYCHIATRIC ILLNESS ON OUTCOME AND CANCER CARE RECEIVED IN PATIENTS WITH GLIOMAS. Neuro-Oncology 2019, 21: vi118-vi118. PMCID: PMC6846933, DOI: 10.1093/neuonc/noz175.494.Peer-Reviewed Original ResearchCancer carePsychiatric illnessPsychiatric diagnosisTumor diagnosisFollow-upPrevalence of psychiatric disordersPresence of psychiatric illnessKaplan-Meier methodPsychiatric disordersPsychiatric conditionsTime of diagnosisSubstance use problemsCompared to controlsAnaplastic oligodendrogliomaMedical careAnaplastic astrocytomaIntracranial gliomasCompare complianceAdjustment disorderIncreased riskPoor complianceGlioma patientsCompare survivalCarePatients